Literature DB >> 2857419

Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer.

J R Sainsbury, J R Farndon, G V Sherbet, A L Harris.   

Abstract

Competitive binding and monoclonal antibody staining techniques were used to demonstrate high-affinity (Kd = 1.9 nmol/l) receptors for epidermal growth factor (EGF) in 35 of 104 primary human breast tumours and in 10 of 14 secondary lymph-node deposits. There was a significant inverse relation between the presence of EGF receptors and the presence of oestrogen receptors in the primary tumours (p less than 0.01), and EGF receptors were found in a greater proportion of metastases than primary tumours (p less than 0.01). These results suggest that the presence of EGF receptors is associated with metastatic potential and that the growth of a proportion of poor-prognosis oestrogen-receptor-negative tumours may be regulated by peptide growth factors interacting with the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857419     DOI: 10.1016/s0140-6736(85)91385-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  116 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 2.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

Review 3.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

Review 4.  Biochemical study of cyst fluid in human breast cystic disease: a review.

Authors:  C L Enriori; J E Novelli; M del C Cremona; R J Hirsig; P J Enriori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Has adjuvant treatment of breast cancer had an unfair trial?

Authors:  I Mittra
Journal:  BMJ       Date:  1990-12-08

Review 6.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

7.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

8.  Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines.

Authors:  C R Carlin; D Simon; J Mattison; B B Knowles
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

9.  The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line.

Authors:  E Helseth; G Unsgaard; A Dalen; R Vik
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

10.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.